The purpose of this study is to see if a drug called mirabegron (MYRBETRIQ) is effective, safe, and tolerated for reducing OAB symptoms while taking tamsulosin hydrochloride for LUTS due to BPH. MYRBETRIQ is approved by the U.S. Food and Drug Administration (FDA) for the treatment of OAB. However, mirabegron (MYRBETRIQ) is not approved by the FDA for use in men also taking tamsulosin hydrochloride. Therefore, its use in this study is considered investigational.
Mirabegron (MYRBETRIQ®) is a prescription drug for adults used to treat overactive bladder (OAB) with symptoms of urgency, frequency, and incontinence (involuntary leakage of urine).
Your participation in this study will last approximately 20 weeks and include 5 study visits to the research center and 1 follow up phone call after the last study visit. This is a randomized, double-blind study to compare mirabegron to placebo.